
CLAIMS

1. A solid form of Compound **I**:




I,

selected from Compound **I** Neat Form A, Compound **I** Neat Form B, Compound **I** Neat Form C, Compound **I** Neat Form D, Compound **I** Neat Form E, Compound **I** Compressed Form A, Compound **I** Compressed Form E, Compound **I** EtOH Solvate Form B, Compound **I** MeOH solvate, Compound **I** NPA solvate, Compound **I** MeOAc Solvate Form A, MeOAc Solvate Form B, Compound **I** MeOAc Solvate Form C, Compound **I** Hydrate Form A, Compound **I** Hydrate Form B, Compound **I** Hydrate Form C, Compound **I** EtOH Solvate Hydrate, Compound **I** MeOH Solvate Hydrate, Compound **I** IPA Solvate Hydrate, and Compound **I** MeOAc Solvate Hydrate.

2. The solid form of Compound I according to claim 1, wherein the solid form is Compound I Neat Form A.

3. Compound **I**:



I,

formulated as a spray-dried dispersion.

4. A pharmaceutical composition comprising:
(i) the solid form of Compound **I** according to claim 1 or 2 or Compound I according to claim 3 and

(ii) a pharmaceutically acceptable carrier.

5. The pharmaceutical composition according to claim 4, further comprising one or more additional therapeutic agents.

6. The pharmaceutical composition according to claim 5, wherein the additional therapeutic agents are one or more additional CFTR modulating compounds.

7. The pharmaceutical composition according to claim 5 or claim 6, wherein the pharmaceutical composition comprises one or more compounds selected from Compound **II**, Compound **IV**, Compound **V**, and pharmaceutically acceptable salts and deuterated derivatives of any of the foregoing.

8. The solid form of Compound **I** according to claim 1 or claim 2 or Compound I according to claim 3, or the pharmaceutical composition according to any one of claims 4 to 7, for use in the treatment of cystic fibrosis.

9. The compound for use of claim 8, wherein the compound is administered in combination with one or more compounds selected from Compound **II**, Compound **IV**, and Compound **V**, and pharmaceutically acceptable salts and deuterated derivatives of any of the foregoing.

10. Use of the Compound **I** according to any one of claims 1-3, or the pharmaceutical composition according to any one of claims 4 to 7 in the manufacture of a medicament for the treatment of cystic fibrosis.

11. The use according to claim 10, wherein the medicament is formulated for administration in combination with one or more compounds selected from Compound **II**, Compound **IV**, and Compound **V**, and pharmaceutically acceptable salts and deuterated derivatives of any of the foregoing.

12. A process for preparing Compound **I** Neat Form A according to claim 1 or claim 2 comprising **(i)** dissolving amorphous Compound **I** in ethanol, **(ii)** increasing the

temperature to about 73 °C, **(iii)** decreasing the temperature to about 20 °C, **(iv)** isolation of the solid via filtration, and **(v)** drying of the solid at 50 °C.

13. A process for preparing Compound **I** spray-dried dispersion according to claim 3 comprising **(i)** preparation of a solution of Compound I and polymer in a DCM/MeOH mixture, and **(ii)** spray drying the resulting solution using a spray dryer.